Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.

Authors: Jiang, Yaofei, Bei, Weixin, Wang, Lin, Lu, Nian, Xu, Cheng, Liang, Hu, Ke, Liangru, Ye, Yanfang, He, Shuiqing, Dong, Shuhui, Liu, Qin, Zhang, Chuanrun, Wang, Xuguang, Xia, Weixiong, Zhao, Chong, Huang, Ying, Xiang, Yanqun, Liu, Guoying

Source: BMC Medicine; 3/11/2025, Vol. 23 Issue 1, p1-11, 11p

Subject Terms: NASOPHARYNX cancer, PROGRAMMED cell death 1 receptors, SAFETY, TREATMENT effectiveness, CYTOTOXIC T lymphocyte-associated molecule-4, CLINICAL trials, CANCER chemotherapy, IMMUNE checkpoint inhibitors

Single‐cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma.

Authors: Jiang, Yaofei, Bei, Weixin, Li, Wangzhong, Huang, Ying, He, Shuiqing, Zhu, Xiaobin, Zheng, Lisheng, Xia, Weixiong, Dong, Shuhui, Liu, Qin, Zhang, Chuanrun, Lv, Shuhui, Xie, Changqing, Xiang, Yanqun, Liu, Guoying

Source: Clinical & Translational Medicine; Oct2024, Vol. 14 Issue 10, p1-25, 25p

Subject Terms: TUMOR antigens, IMMUNE checkpoint proteins, CANCER cells, T cells, INTERFERON gamma